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ABSTRACT: Rising population density and global mobility are
among the reasons why pathogens such as SARS-CoV-2, the virus
that causes COVID-19, spread so rapidly across the globe. The
policy response to such pandemics will always have to include
accurate monitoring of the spread, as this provides one of the few
alternatives to total lockdown. However, COVID-19 diagnosis is
currently performed almost exclusively by reverse transcription
polymerase chain reaction (RT-PCR). Although this is efficient,
automatable, and acceptably cheap, reliance on one type of
technology comes with serious caveats, as illustrated by recurring
reagent and test shortages. We therefore developed an alternative diagnostic test that detects proteolytically digested SARS-CoV-2
proteins using mass spectrometry (MS). We established the Cov-MS consortium, consisting of 15 academic laboratories and several
industrial partners to increase applicability, accessibility, sensitivity, and robustness of this kind of SARS-CoV-2 detection. This, in
turn, gave rise to the Cov-MS Digital Incubator that allows other laboratories to join the effort, navigate, and share their
optimizations and translate the assay into their clinic. As this test relies on viral proteins instead of RNA, it provides an orthogonal
and complementary approach to RT-PCR using other reagents that are relatively inexpensive and widely available, as well as
orthogonally skilled personnel and different instruments. Data are available via ProteomeXchange with identifier PXD022550.
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■ INTRODUCTION
COVID-19 has disrupted daily life in a substantial part of the
world. The virus has forcedmany countries worldwide to impose
lockdowns or take similar wide-ranging measures. To exit such
lockdowns, widespread diagnostic capabilities are required to
prevent reoccurrence of outbreaks.1 Today, millions of reverse
transcription polymerase chain reaction (RT-PCR)-based tests
are performed every day worldwide. Although these are efficient,
relatively simple, and acceptably cheap, reliance on one type of
technology comes with notable disadvantages. Not only does
this regularly lead to shortages of the necessary reagents and lack
of scalable capacity, it also means that these tests are difficult to
validate in terms of sensitivity, false positives, and false negative
diagnoses.2−4 Additionally, nucleic acid alone cannot be used to
define viral shedding or infection potential supporting the
importance of the detection of other biomolecules.5,6 Therefore,
numerous publications aim at expanding the viral targets beyond
RNA.7−18 Like many other viruses, SARS-CoV-2 can produce
virus-like particles (VLPs) that contain a high concentration of
proteins, but no RNA, making these biomolecules very attractive
Received: February 9, 2021
Published: May 3, 2021
Articlepubs.acs.org/jacsau
























































































targets for liquid chromatography mass spectrometry (LC-MS)-
based detection and characterization.19−21 In fact, MS-based
detection of proteins is directly compatible with conventional
clinical small molecule detection setups and is adoptable to new
mutations in a matter of hours, a very relevant feature in light of
the recent D614G variant.22 Additionally, the assay is much less
prone to contamination than RT-PCR-based assays because of
the lack of amplification steps. Thus, in contrast with RT-PCR
setups, no pre- and post-PCR lab infrastructure needs to be set
up, making a roll-out of an MS-based assay relatively easy in
comparison. However, when compared to RT-PCR, MS
instrumentation and matrix effects from transport media are
more pronounced, and no single working protocol can be
expected to be easily implementable across all clinical
laboratories.
Therefore, we here describe a community-based effort that
has led to a generic and widely applicable MS-based template
assay that allows easy adaptation to the broadly variable testing
facility landscape (Figure 1). First, we used our high-resolution
MS instrument data to create a vendor-independent Skyline
document with 17 biomarker peptides from two structural
SARS-CoV-2 proteins detected in public data, i.e., nucleocapsid
(NCAP_SARS2) and spike (SPIKE_SARS2) protein.17,23 We
then established a consortium (MS-Cov), consisting of
academic and industrial laboratories, complemented with
representation from major MS vendors (Waters Corporation,
Sciex, and Thermo Fisher Scientific). All members of this
consortium were provided with the Skyline document together
with a sample kit containing both pure recombinant NCAP and
SPIKE protein as well as a dilution series in a negative patient
background. Fifteen laboratories shared data from four different
instrument vendors, which was gathered centrally and used in a
vendor-independent freeware (Skyline) to assess overall
performance and suitability of the candidate signature
peptides.24 Finally, we have established the Cov-MS Digital
Incubator in the form of a Microsoft Teams environment where
open communication and data sharing will help translate this
assay into different clinical environments around the globe. All
supplementary data are available in the Cov-MS Digital
Incubator. Access requests can be sent to CovMS@ugent.be.
We here present a very detailed and fully accessible report of
the development of a template assay that will enable laboratories
worldwide to assess the feasibility of SARS-CoV-2 MS-based
detection for their specific platform, navigate and share their
optimizations, and quickly adopt the assay in a common effort to
significantly increase testing capacity worldwide in the
upcoming months. Shortly, we will become part of COVID-
MSC.25 The LC-MS data generated within the Cov-MS
consortium is shared and browsable through Panorama Public
(https://panoramaweb.org/CovMS.url); DDA, predicted and
chromatogram libraries as well as the narrow window DIA data
have been deposited to the ProteomeXchange Consortium via
the PRIDE partner repository26 with the data set identifier
PXD022550 and 10.6019/PXD022550.
Figure 1.Cov-MSMRM assay development. The SARS-CoV-2 peptide biomarker discovery workflow (blue) was initiated in mid-March 2020. Using
the recombinant NCAP and SPIKE protein (Sino Biological, Beijing, China), combined with 20 nasopharyngeal swabs from patients, we applied our
recently published data acquisition and data analysis workflow using machine-learning-based spectral predictions.27 With the 17 responsive peptides
discovered in this way, a preliminary MRM assay was developed that could classify all 20 blinded patient samples correctly. We then assembled the
Cov-MS consortium (red) comprising MRM experts from academia and industry, a protein standard company, and a large computational research
group. This consortium was provided a Cov-MS kit containing dilution series of recombinant protein digests to optimize instrumental parameters and
define their limit of detection (LOD). Optimization of sample preparation assessed alternative transport media and consumables (a) increased
digestion efficiency (a′) and reduced the time investment down to 20 min, and optimization of data acquisition involved 15 different laboratories with
different instrumental platforms (b). These were supported by acquisition specialists from three main instrument vendors. By centralizing all data (b′),
instrument-specific peptide targets could be distilled. Optimization of data analysis centered around the correlation between MS signal intensity and
clinical RT-PCR assay Ct value (c). Peptides with the highest diagnostic value were filtered out for each medium through machine learning (c′).
Additionally, all peptide biomarker candidates were mapped to the 3D structure of the target proteins and investigated for SARS-CoV-2 strain
specificity and for known mutations in variants of concern. To enable future clinical roll-out (green), a heavy QConCAT internal standard was
synthesized that enables assessing patient sampling quality, sample preparation efficiency, instrumental robustness, and absolute quantification of the
viral load. We validated the optimized workflow on 135 patient samples. Finally, we established a Microsoft Teams environment (Cov-MS Digital
Incubator) to facilitate global collaboration on the translation of this assay into the clinic. The color-coding in this graphic is used in the rest of the
article to indicate in what stage of the development the results should be framed.
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Figure 2. Discovery phase (blue). (A) Seventeen SARS-CoV-2 responsive peptide biomarkers. Based on public data,17,23 we selected two target
proteins (NCAP_SARS2 and SPIKE_SARS2) and obtained recombinant equivalents (Sino Biological). Using dilution series in a background of 250
μL of UTM from nasopharyngeal swabs of healthy volunteers, we used our recently published workflow combining narrowwindowDIAwith predicted
intensities and retention time to detect a total of 17 responsive peptides.27 Only intensities of peptidoforms that passed the mProphet threshold of 1%
FDR are depicted. The arrowhead indicates a substituted amino acid in the sequence of the recombinant protein. Bold sequences were also reported in
a recent review from Grossegesse et al.18 and in ref 21. Underlined sequences were mapped onto SPIKE_SARS2 (S), NCAP_SARS2 C-terminal
dimerization domain and NCAP_SARS2 RNA binding domain (from left to right). Mapped peptides are highlighted in structures, and the
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■ RESULTS AND DISCUSSION
Figure 1 depicts a schematic overview of the multiple reaction
monitoring (MRM) assay development workflow from
discovery to envisioned implementation. Each step is discussed
in more detail below in a comprehensive and accessible manner
that enables reanalysis of the data online through Panorama
Public interface for a broad outreach.
Discovery Phase (Blue): Finding SARS-CoV-2 Peptide
Biomarkers
Sample Preparation. From the start, sample preparation
was designed for typical nasopharyngeal swabs, i.e., Copan
Universal Transport Medium-RT (UTM-RT). The aim was to
minimize sample consumption, time investment, cost, and
reagent use and to facilitate parallelization. Therefore, 50 μL of
UTM was combined with 450 μL of ice-cold acetone, resulting
in simultaneous protein precipitation and viral-particle neutral-
ization, which allows sample preparation to be performed in a
validated biological safety cabinet (BSC) in Biosafety Level L2
(BSL-2) laboratories.28 The sample preparation protocol
requires only 10 min of hands-on work and only costs a few
euros on reagents. Different grades of trypsin were also
compared (Material and Methods and Supporting Information,
Detailed Methods, Sample Preparation).
Peptide Biomarker Discovery. The recombinant proteins
were analyzed, and a spectral library was created for early assay
development based on fractionation of the sample combined
with data-dependent acquisition (DDA) and data-independent
acquisition (DIA) strategies on high-resolution instruments
(Supplementary Data 1).21,29,30 A detailed description of this
process is presented in Supporting Information (Detailed
Methods - Data Analysis - DIA). DIA data are akin to parallel
reaction monitoring (PRM) data and in the basic form are
identical to what is generated on tandem quadrupole instru-
ments operated inMRMacquisitionmode. Therefore, creating a
targeted method for any tandem quadrupole instrument
becomes trivial, i.e., selecting the transitions that are best
detected on a given tandem quadrupole MS instrument in a
given lab. We therefore opted to share the assay with the
community in this form.
SARS-CoV-2 peptide signals were extracted from the dilution
series that were run by a 64 window SWATH on 75 and 20 min
LC gradients (Supplementary Data 2a and 2b) using a high-
resolution TripleTOF 6600+ Q-TOF instrument (Sciex,
Concord, Canada). We detected 17 responsive peptides that
showed an increase in signal with increased loading (Figure 2A
and Supplementary Data 2c). At least nine of these have been
reported in other studies, confirming that these are indeed
i n t e r e s t i n g t a r g e t s . 1 8 N o t a b l y , o n e p e p t i d e
(IGMEVTPSGTWLTYTGAIK) from the recombinant protein
was not detected due to a single amino acid substitution in the
sequence (G16A). Indeed, Grossegesse et al. recently cautioned
for the pitfalls of using recombinant proteins for target
selection.18 Next, data for the 20 blinded patient samples were
acquired on a 75 min gradient using the 64 window SWATH
mode (Supplementary Data 3a). Through manual inspection of
the data, we correctly classified 18/20 samples (Supplementary
Data 3b). The two positive patients that were classified as
negative at this point had the lowest viral load according to RT-
PCR, i.e., with the highest Ct values of 19 and 20. Notably, the
exploratory DDA approach had detected SARS-CoV-2 peptides
in only two of these 20 patients (Supplementary Data 3c).
Translation into a Targeted MRM Assay with Instant
Clinical Applicability. As a template for all downstream
optimizations, a Skyline project was created on the DIA data,
retaining all 17 peptide biomarkers with 145 transitions
(Supplementary Data 4). Notably, two peptides with a missed
cleavage were retained because they derive from a KK, RR, KR,
or RK amino acid sequence motif.32 To avoid false positive
results, it is important to verify that biomarker peptides are
taxonomically uniquely assigned to SARS-CoV-2 (Supplemen-
tary Data 5), and to understand the evolutionary conservation of
these peptides (Figure 2A). Our taxonomic analysis using
Unipept (Supplementary Data 5) illustrates that some of the
detected peptides are also expressed in other Coronaviridae or
even different organisms.While others have suggested to discard
all nonunique sequences during target selection,16,30 we
maintained these for downstream optimizations. First, a
combination of peptides allows higher specificity18 and accounts
for intrinsic incompleteness of databases. Second, the prevalence
of other organisms in nasopharyngeal swabs is not known, and
these peptides may therefore never occur apart from SARS-
CoV-2 infection. Third, variants of concern could easily escape
detection if only one or two peptides are being targeted. We
therefore mapped amino acid changes of the NCAP protein
from www.gisaid.org, which resulted in an exhaustive overview
of mutation-prone regions, amino acids, and the continents
where they were most prominently found in February 2021
Figure 2. continued
conservation scores are colored red (0% conserved) to blue (100% conserved) scale.31 Black font indicates sequences unique for the SARS-CoV virus
(Detailed Methods section, data analysis). (B) Matrix interference and peptide selection. Irrespective of their evolutionary conservation, all candidate
peptides were retained to allow robust assay development compatible with any matrix, experimental condition, or LC-MS instrument used. Depending
on the sample conservation buffer, intensities and interferences vary greatly, as illustrated by the transition signals from AYNVTQAFGR and
DQVILLINK at 2.5 min without (in-solution) and with an eSwab andUTMbackground. Arrowheads indicate correct peak. Signal within dotted lines,
i.e., peak boundaries, is summed to calculate the LogSumAUC. (C) Intensity−loading correlation in three different backgrounds. The recombinant
proteins were measured in different loading amounts either without matrix (in-solution, n = 1) or in eSwab (saline matrix, n = 1) or UTM (protein
matrix, n = 3) (5 μL medium equivalent on column). Left inset illustrates the impact of the background on low intensity signal. The right inset
highlights the instrumental limit of detection (LOD) and potential limit of quantification (LOQ) of these viral proteins in-solution when all transition
intensities are summed. (D) Correlation betweenMS protein signal and RT-PCR RNA detection. Starting from the Skyline document, anMRM assay
was developed for UTM samples on a Xevo TQ-S instrument (Waters Corporation) by MRM transition selection. The final method comprised 10
peptides with a total of 30 transitions. We applied the MRM assay to the 20 patient samples (number coded according to Supplementary Data 3b) in
UTM obtained from a University Hospital (Leuven). An equivalent of 5 μL (out of 3 mL) of medium of each sample was loaded on column. The
detection results from the Skyline report were used to logarithmically transform the summed AUC (LogSumAUC) of all the peptides. When plotted
against the Ct valuemeasured by RT-PCR, a strong correlation is found (formula allows conversion of Ct into expected signal), which suggests that this
assay can have great potential in the clinic. Negative patients (red) are depicted by their LogSumAUC only beyond the vertical double line on the X-
axis (Ct > 40).
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(Supplementary Data 23 and Figure S1a,b). Most importantly,
however, compared to RT-PCR, implementation of viral
detection MRM assays in the clinic is much more limited by
the variability in sampling background (e.g., blood and mucus),
conservation medium, and instrument specifications. Therefore,
the intensities, retention times (tR), and interferences of
transitions between different samples can vary greatly when
the matrix is not removed. To illustrate this, we depict the signal
of AYNVTQAFGR and DQVILLINK, both at a tR of 2.5 min, as
these were measured without matrix (in-solution), in UTM
Figure 3. Cov-MS consortium report (red phase). (A) Sample preparation optimization. Different storage media, TCA precipitation, and a 15 min
digest (n = 5) were compared. The increased LogSumAUC is expressed as log fold changes. (B) Comparing different sample preparation consumables.
In the standard workflow, peptides were dissolved in water and transferred to spring insert (SI) sample vials. Using Quan Recovery (QR) vials and
adding 5% acetonitrile (ACN) to the solvent increased the signal for most peptides in solvent but not in UTM (Supplementary Data 10). The bottom
bar displays the estimated overall gain attributed to consumables. (C) Increasing the sample load for eSwab samples. Because eSwabs use saline-based
preservation solution, increasing the amount of sample on column can be beneficial. Therefore, we assessed the impact of increasing the loading 5-fold,
either with or without SPE. An overall average LogSumAUC fold change of 2.3 (dotted line), i.e., 5 times increase in signal, can be attained if the sample
is split in five and SPE is applied (LogFold 5 × 50 SPE). (D) Data acquisition within the Cov-MS consortium. Fifteen laboratories optimized
acquisition on their instrumental platforms using the SOP, the Cov-MS kit, and the Skyline project provided. The bubble plot represents the relative
abundance of each peptide in the dilution series compared to the highest abundant peptide for that lab. Strikingly, each lab detected a different
(collection of) peptide(s) as the best targets. Several laboratories could detect signal down to 0.2 ng on column in the UTM background. LAB_14 is
depicted with shading because this instrument was fitted with a UniSpray source. (E) Optimization of the data analysis. We developed a more data-
driven scoring function as an alternative to simple summation of all signal (LogSumAUC). Therefore, a model was trained using all features exported
from the Skyline document of 70 patient samples from the AZDelta sample batch. The principal component analysis (PCA) scoring the distribution of
all features illustrates that the conservation medium is one of the most prominent variables in the data set. (F) Peptide feature weighing. The feature
weights that are given to each of the MRM transitions by the ML algorithm are representative of their diagnostic value. This in turn can be used to
calculate the contribution of each peptide to diagnostic outcome. (G) Final peptide ranking in two different media. From the upper left to the lower
right, peptides are depicted by their ML rank in both media. Three peptides could be universally applicable (on a Xevo instrument), irrespective of the
medium.
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(dominant protein background) and in eSwab medium (saline
background) with 1 ng on-column (the amount of protein
sample analyzed in an LCMS run) (Figure 2B). In conclusion,
we recommend targeting all 17 peptides as a starting point in
every unique setup where the assay will be implemented. The
rollout of an MRM assay is then reduced to omitting those
MRM transitions with the poorest performance for that site.
Using this Skyline document, the first MRM assay was
optimized on a Xevo TQ-S (Waters Corporation, Milford, MA).
It contained 10 peptides, measuring 30 transitions (Detailed
Methods section and Supplementary Data 6 and 7). Figure 2C
shows that summing the intensities of these 30 transitions
(irrespective of individual peak shapes or signal-to-noise)
provides a robust metric to quantify dilution series of SARS-
CoV-2 proteins with and without a matrix. However, the
preservation medium has a considerable impact, as shown by
background inflation of low signals (in-solution < eSwab <
UTM, Figure 2C left inset) and by matrix suppression of more
abundant signals (in-solution > UTM > eSwab). Notably,
SPIKE could still be detected down to 70 amol (10 pg) on
column and NCAP down to 40 amol (2 pg) on column in
solution. This is referred to as the instrumental limit of detection
(LOD) (Figure 2C right inset and Supplementary Data 6). In
fact, LogSumAUC still allows one to distinguish 0.001 and 0.002
from 0 ng on column, whereas no clear peaks could be annotated
in the Skyline project. This implies that summing intensities at
specific retention times could be a more robust metric than
trying to call single peptide peaks. At 10 pg on column, the
summed intensity of all transitions was higher than that of 2 pg,
making this the potential instrumental limit of quantification
(LOQ). Assuming 300 NCAP molecules in a viral particle, as
few as 80000 particles can thus theoretically be detected without
matrix, in line with previous reports.9,11,33
Finally, this optimized MRM assay was applied on the 20
UTM patient samples obtained from University Hospital
Leuven, which had been previously diagnosed using RT-PCR.
The RT-PCR result is measured by the number of RNA
duplication cycles required to detect viral RNA, designated the
Ct value. Therefore, peak boundary corrected transition
intensities were summed and Log2-transformed (LogSumAUC)
and correlated with the RT-PCR Ct values. From these 5 μL
UTM on column LC-MS experiments, a strong inverse linear
correlation (R2 = 0.9118 with the three negative samples
excluded) was found between the LogSumAUC from Skyline
and the Ct values measured in the clinic (Figure 2D and
Supplementary Data 7). This strong correlation was already
suspected18 and makes an overwhelmingly strong case for the
diagnostic potential of the protein-based MRM assay.
Cov-MS Consortium (Red): Increasing MRM Assay
Sensitivity and Robustness
Based on the observed linear correlation between the measured
peptide intensities and the RT-PCR Ct values (Figure 2D), the
LOD of the assay, i.e., its sensitivity, was redefined in the context
of Ct values measured in the clinic. This comparison allows
improvements to the assay to be expressed in terms of number of
Ct cycles gained, with one Ct cycle corresponding to a doubling
in sensitivity. Indeed, for a larger batch of patient samples (n =
86; 5 μL medium equivalent on column) from another hospital
(AZ Delta) and that included higher Ct values and different
media (Supplementary Data 8), the decrease in LogSumAUC
stalled around Ct 20, and there was no difference in measured
signal-to-noise (S/N) at higher Ct values. Therefore, the next
challenge was redefined as increasing the S/N in order to gain as
many Ct values as possible, i.e., to gain detection doublings. In
essence, this implied straightening of the curve (Figure 3).
On April 21, 2020, we presented our discovery phase and
preliminary results online to over 80 interested parties to
establish a consortium (Cov-MS) to broaden the scope of the
work, transfer the methods to other (vendor) instruments, and
bring in the expertise of other functions and scientists.34 This
allowed parallelization of the sample preparation, data
acquisition, and data analysis optimization (Figure 1).
Sample Preparation Optimizations: 2−3 Ct Values.
Efforts focused around three optimizations: applying a different
precipitation strategy with acid, i.e., trichloroacetic acid (TCA)
and hydrochloric acid (HCl), reducing digestion time to 15 min,
and using different conservation media. While many of these
changes increased the overall signal (Figure 3A and Supple-
mentary Data 9), the best protocol is typically dependent on the
MRM assay under development as many changes are peptide-
specific and might be attenuated by increased ion suppression or
noise depending on the medium, sample-related specifics, and
experimental conditions. Nevertheless, the reduction of the
digestion protocol to only 15 min (with Promega Trypsin-Lys-C
Mix, mass spec grade) now enables a complete sample
preparation workflow of less than 30 min.
In parallel, the use of different LC columns, sample vials, and
resuspension protocols were also investigated, alongside peptide
stability (Figure 3B and Supplementary Data 10). Beneficial
effects were incremental, on the order of 10−20% gains in
LogSumAUC for (i) using 5% acetonitrile for redissolving the
peptides, (ii) using dedicated sample containers (QuanRecov-
ery Vials, Waters Corporation, Milford, MA), and (iii) reversed-
phase separation columns to minimize nonspecific binding
(ACQUITY PREMIER Peptide BEH C18 Column, 300 Å, 1.7
μm, 2.1 × 50 mm, Waters Corporation, Milford, MA). Notably,
the gain is lower in UTM background, most probably due to
carrier protein effects in this medium.
Crucially, the biggest limitation in terms of sensitivity is the
amount of sample that can be loaded on column. More
specifically, the results from the discovery phase (blue) were all
attained on 5 μL medium equivalent on column. Unfortunately,
increasing sample load using solid-phase extraction is not
straightforward for MRM assays. A detailed description on the
main concerns can be found in the Detailed Methods section.
Still, the fold changes of each peptide are shown in the
anticipated 5-fold increase in signal (dotted line); that is, a
minimum of two Ct values can be attained if five times 50 μL
digest solution is concentrated onto a single SPE column
(Figure 3C and Supplementary Data 11). Automation will allow
this finding to be consolidated and extended, yet we caution here
for SPE overloading. Given the lack of in-house automation, we
continued with the original protocol on a 50 μL sample and 10
μL injection on column without applying SPE.
In conclusion, all validated sample preparation strategies have
a peptide-specific effect. Therefore, it is worth re-evaluating
these steps once the final peptide selection for an assay has been
made.
DataAcquisitionOptimization: 1−2Ct Values.After the
online presentation of the assay on April 21st, 2020, many of the
attendees joined the Microsoft Teams Cov-MS team then
containing three channels, one per participating vendor (Waters
Corporation, Sciex, and Thermo Fisher Scientific). At the time
of submission, the group counted over 100 participants. The
Cov-MS laboratories were encouraged to discuss method
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optimization with the vendors’ international expert support
teams.
To streamline the integration of all these parallel optimiza-
tions, consortium members were provided a detailed standard
operating procedure (SOP) for method optimization, the
Skyline template containing the 17 peptides (145 transitions),
and a Cov-MS kit (Supplementary Data 12). These kits
contained digests of pure recombinant NCAP and SPIKE
protein as well as a dilution series in a UTM background from
healthy donors, in triplicate. The kits allow members to
standardize the optimization protocol, to assess performance
under different circumstances, and to centralize all data to distill
best practices per vendor. Figure 3D summarizes overall peptide
detectability for 15 participating laboratories. Individual
instrumental platform data are provided in Supplementary
Data 13 and 14 in an easily handled pivot table format. Data can
be browsed directly (https://panoramaweb.org/CovMS.url) in
Panorama Public. Several partners compiled detailed reports,
and Sciex andWaters Corporation published several application
notes based on their data35−38 (Supplementary Data 15).
Importantly, only the latest generation tandem quadrupole
instruments can reach adequate sensitivity. Additionally, the
compiled results confirm the initial hypothesis that peptide
selection is lab-specific. This was recently also described in a
Figure 4.Toward translating the Cov-MS assay into the clinic (green phase). (A) Cov-MSQConCAT internal standard. An isotope labeled (“heavy”)
construct was expressed in E. coli to troubleshoot and standardize assay development. It contains the 17 stable-isotope-labeled (SIL) SARS-CoV-2
peptides for absolute quantification (red and orange), three RePLiCal peptides to assess LC system stability (green), and four host peptides derived
from histones to assess the efficiency of the swab sampling procedure (dark blue). (B) Facilitating peak detection using the Cov-MS internal standard.
The two peptides from Figure 2B are depicted in red in their most interfering matrix. The blue trace depicts the heavy signal from the Cov-MS SIL (2
ng and 2.5 ng on column), showing how peak detection now becomes automatable. (C) In-house Ct values for a dilution series of viral particles from
the National Reference Center in Belgium. We generated a dilution series in two different backgrounds and determined the Ct values using our in-
house RT-PCR assay. eSwab consistently gave higher Ct values compared to Copan UTM-RT in our hands, but the detection limits attained would
allow for accreditation of our RT-PCR workflow. (D) Patient dilution series as an alternative assessment procedure. The viral particle used in the
dilution series presented in (C) did not yield any reliable signal in theMRM assay. Therefore, four patients with comparable in-house Ct values in four
different backgrounds were selected and diluted in their respective background of negative patients. TheX-axis depicts the theoretical Ct values in such
dilution series according to (C) and the y-axis represents the LogSumAUC of the 13 peptides retained in this MRM assay (Supplementary Data 19).
The Cov-MSQConCATwas not yet included in this experiment. Most notably, eSwab retains a linear correlation with intensity below a LogSumAUC
of 18, which is not noticeable in the other media. The inset shows the results when only the best three peptides from the ML (Figure 3G) are used for
eSwab andUTM. (E) Large patient cohort. Inset: 89 clinically positive patients (dark green) were first selected for in-house RT-PCR (light green), and
both Ct values were compared. Negative in-house results are depicted on the X-axis. The arrow (inset) highlights the discrepancy between the eSwab
clinical and in-house Ct values for the patient used for the dilution series in (D). All patients with a clinical Ct below 30 were positive in both assays and
were retained for MRM assay validation (n = 82). Using the best three peptides from the ML (Figure 3G), the LogSumAUC was plotted against the
clinical Ct value. Negative patients are depicted to the right to sample the noise. The outliers are circled in red. The horizontal line shows the
LogSumAUC_Rank3 below which signal cannot be confidently distinguished from noise in UTM (blue) and eSwab (orange). For both media, the
cross section with the linear regression line is projected downward to estimate the theoretical sensitivity in terms of Ct value.
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review on currently available MS-based detection assays.18
However, because the data in this study were acquired on the
same samples and analyzed using the same software, it is possible
to draw direct conclusions on the acquisition itself. These
preliminary results imply that different vendors could benefit
from different sets of target peptides, even if the same transitions
were targeted (Figure 3D). One striking example is the
RGEPQTQGNFGDQELIR peptide, which is especially prom-
inent on Sciex instruments, possibly because the corresponding
ion sources are better suited to higher charged peptides. The
impact of the source is best illustrated by LAB_14 that used a
UniSpray source (Waters Corporation) instead of an ESI source,
which boosts the ionization of the ADETQALPQR peptide
compared to all other laboratories.37 The latter is especially
interesting in light of a previous report that argues for this target
peptide.18,39 While this remains to be fully confirmed by the
growing Cov-MS consortium and beyond, including ionization
efficiencies in MALDI sources, the drafting of vendor-specific
best practices will likely be important for streamlined lab-specific
assay rollout. As a starting point, four different technical notes
from two vendors are already published.35−38
Data Analysis Optimization: 1−2 Ct Values. Figure 2D
depicts the quantitative MRM results as the LogSumAUC of all
ions within the peak boundaries of the transitions in that
particular assay. The initial selection of these transitions was
based on an expert’s choice from the Copan UTM-RT dilution
series in the Cov-MS kit. However, not all transitions contribute
to diagnosis equally, and excluding those transitions that are
subject to interference in a specific matrix, have low signal, or are
simply redundant allows retention of the best transitions in the
final LogSumAUC and increased instrumental dwell times to
boost sensitivity. However, because of the high variability, this
can only be attained by a data-driven approach.
To construct such a data-driven scoring function to
distinguish between positive from negative COVID-19 patients
from the MRM data, a machine learning (ML) model was
trained and evaluated (Supporting Information, Detailed
Methods). The training and evaluation data consisted of a
Skyline document export of 70 LC-MS experiments on a Xevo
TQ-S (Waters Corporation) accompanied by relevant meta-
data: healthy or diseased, medium used, andCt as determined by
RT-PCR at the time of initial diagnosis (Supplementary Data 8).
The full script and the weights of the individual transitions is
available in Supplementary Data 16 and on github (https://
github.com/compomics/Cov-MS-scoring).
The principal component analysis of the feature scores
exported from Skyline clearly illustrates that the medium is the
most prominent contributor to the second principal component
and thus to the choice of transitions and the attainable
diagnostic value (Figure 3E). Therefore, in a second round,
we trained the two patient populations separately (eSwab, n =
29, and UTM, n = 41). Figure 3F depicts the diagnostic weight
of each peptide in the respective media.
By plotting the order in which the peptides appear in both
media a common set of three peptides surfaced that appears to
be well suited for both Copan UTM-RT and eSwab transport
media. Even more excitingly, these three peptides cover both
SPIKE and NCAP structural proteins (Figure 2A), making this a
very attractive target selection (Figure 3G).
In conclusion, all parts of the workflow impact each peptide
differently. While there is great agreement on the topmost
applicable targets, the final order in which a lab can detect them
still shifts considerably. Therefore, standardization will be
essential for any MS-based assay, and each platform will target
different sets of peptides, akin to the use of different primers in
PCR laboratories.
Toward a Clinical MRM Assay (Green)
From the start, our joint efforts have focused on fast and efficient
clinical applicability. Therefore, we retain the matrix, reduce
sample preparation to below 30 min, provide kits, SOPs and
software methods, and only use tandem quadrupole instruments
in configurations that are readily available in the clinic. Finally,
we describe the first steps in standardization and validation of
the assay for clinical implementation and present our Cov-MS
Digital Incubator to facilitate communication and exchange on
further improvements.
Cov-MS Internal Standard Assesses Sampling Effi-
ciency, Sample Preparation, Data Acquisition, and Data
Analysis Automation. In clinical MS-based assays, stable-
isotope-labeled (SIL) internal standards are indispensable to
meet measurement accuracy and to satisfy regulatory require-
ments. For this assay, together with PolyQuant, we designed the
Cov-MS QConCAT, i.e., an artificial protein comprising
concatenated peptides to allow for absolute quantification40
(Figure 4A). It not only allows to report absolute viral load and
interlaboratory comparison, it also enables validation of the
entire workflow: (i) swab sampling procedure efficiency in the
clinic, (ii) sample preparation efficiency, and (iii) instrument
stability, all while (iv) greatly enhancing automation potential of
the data analysis. Briefly, PolyQuant (Bad Abbach, Germany)
joined the Cov-MS consortium and initiated the expression of a
QConCAT protein construct inE. coli that contains the 17
peptide biomarkers. These are heavy labeled through the
incorporation of 15N and separated by their native amino acid
context to assess the efficiency of the digest. Additionally, three
RePLiCal (i.e., a QconCAT protein for retention time
standardization in proteomics studies) retention time standard
peptides were incorporated to help assess LC stability.41 Finally,
four peptides, one from each of the human core histone proteins,
were added to the labeled construct to serve as host protein
markers for swab sampling quality. We reasoned that nuclear
proteins will only be present if the swab caused superficial tissue
damage to release intracellular viral particles from cells.
Therefore, when histones are low or absent, this could point
toward poor swab sampling efficiency and thus a potential false-
negative result. Indeed, all 20 patients from Figure 2D contained
at least one of these four histone peptides in the DDA runs
(Supplementary Data 3C and 17). Therefore, the MS-Cov
QconCAT construct will help in end-to-end assay trouble-
shooting and enables the direct comparison of results from all
over the world. Note that QconCAT is as scalable as SIL
peptides, albeit at a higher cost. Also, in order to include variants
of concern, a new construct needs to be expressed.
A Skyline document comprising both “heavy” (from the
QcontCAT protein) and “light” (from the native viral and
human proteins) transitions was compiled, and three on column
loadings were compared for both UTM and eSwab (Supple-
mentary Data 17). Figure 4B shows the compiled signal of the
light and heavy form of the two peptides from Figure 2B in their
most interfering matrices. It is clear that the heavy signal
(detected here by one transition) greatly facilitates correct peak
detection. The discussion on peak detection automation in
Skyline can be followed in the Skyline support discussion
thread.42 Notably, 1.25 ng was loaded in the final patient batch
to avoid native peptide ion suppression, but this turned out not
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to be enough, especially in Copan UTM-RT background.
Additionally, it might prove beneficial in the future to target
more transitions of the heavy and light peptides to facilitate peak
detection and retain the dotp value as an additional feature in the
Skyline report. Finally, we noted that nearly all peptides (from
the QConCAT) display a forward retention time shift in Copan
UTM-RT background compared to eSwab (Supplementary
Data 17).
RT-PCR Accreditation Standard and Ct Values Are Not
Easily Transposable to an MRM Assay. For external quality
assessment, we requested positive control material from the
National Reference Center (NRC) in Belgium. Developed for
RT-PCR, this purified heat-inactivated virus is used to create a
dilution series that allows laboratories to determine their LOD.
These are series of 1/2 dilutions, each thus corresponding to one
Ct cycle. The starting solution (dilution 0) was said to be the
equivalent of a Ct 17 in the hands of the NRC (Supplementary
Data 18). By simply applying the formula of Figure 2D, a linear
correlation with their patient Ct values would allow us to easily
detect the first few dilutions, i.e., by a predicted LogSumAUC of
19.3. However, because different RT-PCR assays can vary up to
orders of magnitude in the number of copies that can be
detected,3 we first developed an in-house RT-PCR assay using
plasmids as targets. Applying the manufacturer’s instructions, we
were able to detect down to 10 copies of the N-gene plasmids at
a Ct of 38, which corresponds to 2.5 copies at Ct 40, the
theoretical upper limit for RT-PCR diagnosis (Supplementary
Data 18).
We then measured this NRC dilution series in negative
patient background with our in-house RT-PCR assay and could
detect the N1 gene after 10 (Ct 36) and 14 (Ct 38) 1/2 dilutions
in eSwab and UTM, respectively, which would allow for
accreditation (Figure 4C and Supplementary Data 18).
However, this still was 5−6 Ct values higher than in the hands
of the NRC. Additionally, several attempts to detect a peptide
signal in these standards by means of LC-MS failed. This is most
surprising given the fact that the patients in Figure 2D were
analyzed with 5 μL medium equivalent on column and that we
now loaded up to 100 μLmedium equivalent for these standards
using an optimized acquisition and sample preparation strategy.
We attribute this outcome to (a combination of) any of the
following reasons: (i) sample degradation (both mRNA and
protein), (ii) specific in-house sample preparation steps being
incompatible for the specific purpose of detecting proteins in
these purified viral particle standards, (iii) the heat inactivation
step, or (iv) the potential role played by viral-like particles
(VLP),19,20 which were not present in these ultracentrifuge
purified standards. In other words, in patient samples, a higher
signal for proteins could be present than would be theoretically
anticipated from the RT-PCR positive control set. This implies
that proficiency assessment schemes for this assay will only be
possible through an alternative assessment procedure (AAP), as
is often the case when different biomolecules are targeted in
clinical assays (see section 9.1.1 from CLSI 62-A).
We therefore propose patient dilution series as an AAP. More
specifically, a dilution series of positive patient samples in the
respective sample buffer from negative patient samples allows
assessing the sensitivity of the optimized MRM assay in terms of
Ct value. We made four such dilution series in four different
matrices, now also including Virocult (a balanced salt solution
containing antibiotics to inhibit the growth of any bacterial
contaminants in the specimen) and Bioer (RNA preservative
medium that enables viral inactivation). We selected four
patients with a comparable in-house Ct value, and based on
Figure 4C, we assume that every 1/2 dilution increases the Ct
value by one. Figure 4D shows the LogSumAUC of all peptides
because no ML has been done on Bioer and Virocult at this
point. Most notably, the eSwab signal retains its linear
correlation to Ct value down to a much lower signal, which is
indicative of a lower background signal, i.e., lower noise and
interference compared to the other media (Supplementary Data
19). In fact, when only the rank three peptides for Copan UTM-
RT and eSwab are used to present the results, the linearity in
Copan UTM-RT persists, as well, albeit at a much shallower
slope, implying that the ML possibly has selected for peptides
with fewer interferences (Figure 4D inset).
Note that our in-house RT-PCR consistently has a higher Ct
value in eSwab compared to the Copan UTM-RT (Figure 4C),
and that the patient that was used for the eSwab turned out to
have a large discrepancy between the in-house and clinical Ct,
even after a second run (red arrow in Figure 4E). Additionally,
we have been presenting the strong correlation between Ct and
LogSumAUC as a measure to assess the performance of an
MRM, yet such correlation does not need to be linear in patient
batches. In fact, a large discrepancy in the MRM signal between
two patients with identical Ct values could have relevant
biological grounds; for example, it might be an indication of an
infectious or “superspreader” phenotype or correlate with the
symptomatology and/or with (anticipated) severity of disease.
We therefore argue against setting a specific Ct value as a
threshold for MRM assay sensitivity and emphasize that the
focus of interpretation of these results should be on the low noise
level in eSwabs rather than the actual Ct values. Others have also
avoided reporting such a direct link.21
In conclusion, a solid validation of this AAP is required before
it can be universally adopted. In fact, measuring increasingly
large patient cohorts, ideally along with documentation of
(absence or presence of) symptoms could prove more useful to
validate the performance of an MRM assay in a clinical setting.
Large Patient Cohort for Assessing Potential Assay
Performance. As a final validation of the current performance
of our Cov-MS assay, we analyzed 325 patient samples with the
optimized conditions from the Cov-MS collaboration on a Xevo
TQ-XS instrument (Waters Corporation) (Supplementary Data
20). To be able to compare the four different media in this batch,
we prepared only 50 μL of each sample, followed by
precipitation and resuspension in 25 μL digest buffer and 10
μL injections, i.e., 20 μL medium equivalents on column. In
parallel, we diagnosed 89 positive patients in the batch with our
in-house RT-PCR. Remarkably, at lower Ct values, we
consistently measured a higher than expected Ct value. At
higher Ct values (>30), many of the patients did not even yield
any signal for the N gene in-house (Figure 4E inset). This can be
explained in part by the fact that the clinical RT-PCR was done
onmore samples.More specifically, the starting (190 vs 140 μL),
elution (40 μL vs 60 μL), and final input volume (8 vs 5 μL)
together indicate that our in-house assay only uses 30% of the
volume in the PCR reaction, i.e., ∼10 μL, compared to the
clinical assay, corresponding to nearly 2 Ct values. Additionally,
these samples had been preserved in the freezer at −20 °C for
over 4 months, and potentially mRNA degradation was
prominent. Finally, low positive patients can be expected to be
more prone to drop-out in the higher Ct range, i.e., after a larger
number of amplification cycles, wherein error too can
accumulate. Therefore, we only used patients with clinical Ct
values below 30 as positive and with negative clinical diagnosis as
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Figure 5. Projection of MRM capabilities. (A) Absolute quantities theoretically correlate Ct to the MRM assay. Ten genomes present in 10 μL are
detected by a Ct of 38 in perfect conditions (i.e., plasmids) with our in-house RT-PCR. Assuming 300 NCAPmolecules per virion, a direct translation
into attomoles is possible. The highlighted portion of the table depicts (B) three different limits of detection for the MRM assay. (i) AYNVTQAFGR
with the Cov-MSQConCAT in eSwab background, (ii) following peptide enrichment (signal taken from in solution dilution from Figure 2B), and (iii)
possibly by more data-driven approaches or summing all signal at the elution window of peptides without peak integration. (C) Potential practical
correlation between Ct andMRM assay. By loading up to 32 times more by enrichment of targets could yield another 5 Ct values of sensitivity. This is
enforced by the fact that clinical RT-PCRs are expected to be higher than on plasmids and the MRM signal could be higher because of VLPs.
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negative. Note that this high degree of variability between RT-
PCR assays again impairs an easy definition for specificity and
sensitivity of the MRM assay based on a Ct threshold.
Figure 4E shows the final outcome of the MRM assay using
the rank 3 peptides from Figure 3G on the remaining 82 positive
patients, i.e., 37 positive patients in Copan UTM-RT, 30
patients in eSwab, 11 patients in Bioer, and 4 patients in
Virocult. Fifty-six negative patients in eSwab22 and Copan
UTM-RT33 were subjected to the same manual peak boundary
curation to define the background signal. Notably, the Cov-MS
QConCAT construct was not detectable in all samples because
the standard turned out to be underloaded at 1.25 ng on column
and was only used to facilitate a manual setting of peak
boundaries. Thus, 138 out of the 325 patients were used in the
final data analysis of the large patient cohort. Raw data of all runs
are available and browsable on the Skyline Panorama server
(https://panoramaweb.org/CovMS.url). As an alternative to
setting a hard Ct threshold, the minimum background threshold
is highlighted for Copan UTM-RT and eSwab, and the
intersection with the linear regression of the positive patients
is projected onto the Ct axis. This is the Ct above which the
background, i.e. matrix, becomes too high to distinguish signal
from noise, and we currently consider this to be the theoretical
maximum sensitivity using the current workflow. All patient
samples were analyzed in a randomized sample list (Supple-
mentary Data 20), and at least some of the background outliers
of eSwab could be attributed to the fact that they were run
closely following a Copan UTM-RT sample and were subject to
carry-over. In conclusion, background, i.e., matrix and not
instrumental limitations, is currently the limiting factor for
increasing the sensitivity.
We conclude that nonproteinaceous buffers are the only
matrices that allow easy adaptation of the assay and to diagnose
patients with Ct values above 20 without matrix removal. In fact,
we strongly argue against the use of the protein-laden Copan
UTM-RT for MS-based SARS-CoV-2 diagnosis given the
reasons mentioned before. In fact, adopting a transport medium
without protein or salts, which coordinately inactivates the virus,
like 70% ethanol, would greatly facilitate sample processing and
potentially improve sensitivity. In brief, the maximum attainable
single-shot MRM would thus start with direct ice-cold acetone
precipitation (7 volumes) on 175 μL of saline medium in 1.5 mL
Eppendorf vials, resuspending this in 35 μL of 50 mM TEABC,
0.5 μg of trypsin/LysC, and 5% acetonitrile with 10 ng of Cov-
MSQConCAT standard, digesting for 15min at 37 °C, followed
by addition of 3.5 μL of 10% formic acid (end concentration 1%)
andpossibly following SPEinjecting 10 μL on column. This
is 45.5 μL medium equivalent on column, or 2.25 times more
than the patient batch analyzed here. While it is currently not
proven that increasing the loading increases sensitivityas the
matrix background increases accordinglywe are confident that
Cov-MS has strong potential of becoming a valuable addition to
the diagnostic SARS-CoV-2 toolbox in the near future.
Cov-MS Digital Incubator: Facilitating Improvements
for Clinical Roll-Out. Taken together, the high degree of
variation in matrices and instrumentation was intercepted in this
study by collaboration in the Cov-MS consortium. Uniquely,
both academic and industrial partners have shown inspiring
openness in a joint effort to quickly extend testing capacity and
help alleviate pressure on current testing facilities. As this is
possibly the first peptide-centric viral detection assay to be
rolled-out in the clinic on a large scale, a lot of different
perspectives on the best workflow exist in parallel, and
collaboration allows one to quickly assess the best performing
steps. Currently, such a collaborative effort is also driving the
clinical roll-out in the Moonshot project in the UK,43 which in
turn is based on the Cov-MS assay and initiatives like COVID-
MSC.25 Also in The Netherlands, institutionally driven efforts
have been initiated. In order to facilitate further exchange of
information, we therefore propose to persist the collaborative
nature of this effort and we invite all interested parties with MS
capabilities to join the Cov-MS Digital Incubator Microsoft
Teams environment, so they can access all information gathered
during this initial phase of development and can parallelize
further efforts to improve applicability, robustness, and
sensitivity of the assay. Current template threats are available
for Waters Corporation, Sciex, Thermo, Shimadzu, Bruker,
Agilent, and PerkinElmer. Access can be requested by sending
name and affiliation to CovMS@ugent.be.
■ FUTURE PERSPECTIVES
We provided a detailed description of a community effort to
build a robust and sensitive orthogonal assay to diagnose SARS-
CoV-2 positivity. To be able to track and align with the millions
of RT-PCR tests that are performed daily, a collective effort by
the scientific community is paramount, not in the least because
MRM assays have rarely been used before to detect viruses.18
Therefore, we invite other laboratories to build on this platform
and to introduce further optimizations across all parts of the
workflow to help translate this assay into mainstream clinical
laboratories and even to potentially start adding other pathogens
to the assay. Here, we list some of the most pertinent issues and
propose some potential solutions.
Increasing Sensitivity
Figure 5A displays the calculations that allow to discuss future
improvements in terms of absolute numbers of genomes. Briefly,
a perfect RT-PCR assay (as was done in-house on plasmids,
Supplementary Data 18) detects 10 genomes in 10 μL at a Ct of
38, i.e., 2.5 genomes at Ct 40. With every virion carrying 300−
350 NCAP molecules,33 the absolute amount of NCAP (in
attomole) in 10 μL is easily calculated. Therefore, the question
becomes what can still be detected by current MS instruments.
We distinguish three different thresholds (Figure 5B): (i) the
signal attained in the current assay, i.e., in eSwab background
with a QconCAT for efficient peak picking of low individual
signals, (ii) pure peptides, i.e., how individual signals could look
like following purification, and (iii) the last evidence we found of
potential signal by LogSumAUC without individual peak calling
on a Xevo TQ-S (Figure 2C,D and Supplementary Data 21).
The latter shows what even more sensitive instruments like the
Xevo TQ-XS (Waters Corporation) or the 7500 System (Sciex)
could potentially still see as a peak. Still, Figure 5C depicts
increased Ct thresholds to illustrate what could happen if target
peptides are first enriched, and up to 320 μL is used in a single
shot (32 times more, i.e., 5 Ct values). Other factors can also
contribute to a shift in Ct values compared to the absolute
number of genomes: (i) patient Ct values can be higher in
clinical laboratories compared to the perfect plasmid situation
and/or (ii) the potential presence of viral-like particles could
boost the signal of an MRM assay. Based on these calculations,
we predict that a clinical Ct value of 30 will most probably be the
maximum attainable for current mass spectrometry instruments.
The Cov-MS laboratories have shown that the latest
generation tandem quadrupole instruments are sensitive enough
to detect patients passed a Ct 20 in the medium. In eSwab, a
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LOD of NCAP of at least 0.1 ng on column (40 amol) was
attained when the Cov-MS QConCAT was used for peak
picking on the latest generation instruments, i.e., a 7500 from
Sciex (Supplementary Data 21), in line with our earlier LODs
depicted in Figure 2C. However, moving beyond Ct values of
25as implied before on high-resolution platforms10,39,44will
thus require enrichment. Protein or peptide immuno-enrich-
ment can be done either through antibodies (e.g., SISCAPA) or
aptamers.45,46 This way, the few molecules that are present in a
sample can be measured almost perfectly, i.e., in isolation with
minimal interference. In the process, this will open the way to
other COVID-19 sampling matrices, like gargle solution, saliva,
and plasma, and finally alleviate the pressure from ever-changing
media being used in the clinic. Together with the Cov-MS SIL
standard that ascertains the correct detection of low signals and a
low coefficient of variation, this could lead to an automatable,
robust, and sensitive alternative for RT-PCR. Finally, enrich-
ment strategies are insensitive to dilution. More specifically, it
was recently suggested that for Belgium a population-wide
weekly screening could be possible if patients are pooled by 32.47
This is the equivalent of lowering sensitivity by 5 Ct values for
RT-PCR but with SISCAPA enrichment; no loss in signal would
be expected.
Will this be enough to become clinically relevant? Well, the
limit of contagiousness was previously estimated to be close to
Ct 33.48
Increasing Throughput
A major drawback of the current LC-MS based workflow is that
data acquisition cannot be parallelized on a single instrument,
contrary to RT-PCR assays that use multiwell plates. Yet, using 8
min gradients, one instrument can already measure over 150
patients/day and by multiplexing LC pumps this can be
increased to ∼500 per day21. One member of the consortium
(Alderley Analytical) additionally looked at the application of 2
min gradients and showed that these should be feasible when the
matrix is relatively clean (Supplementary Data 15), increasing
the throughput to 600 patients per instrument per day without
parallelization. With prior immuno-enrichment like SISCAPA,
gradients as low as 1 min are within reach, as our preliminary
results show (Supplementary Data 22 and Figure S2). At least
from the sample preparation perspective, there is no reason why
robotics cannot be deployed, as is the case for RT-PCR
preparation.
One disruptive recent technology to further increase
throughput is acoustic MS. In the implementation from Sciex
(EchoMS), nanoliter droplets are acoustically ejected from the
sample and into the instrument at a rate of 3 Hz, with each
droplet measuring up to five transitions.49 In time, this could
lead to sampling an estimated 30000 patients a day per
instrument. Likewise, MALDI-ToF instruments could provide
very high throughput following immuno-enrichment of target
peptides.
Screening Multiple Pathogens in a Single Assay
Using the proposed workflow, it is relatively straightforward to
add mutations or even other pathogens for screening in a single
assay. These include other corona viruses as well as influenza.
This will greatly increase the impact of protein detection by
MRM in the clinic.
Making Data Analysis Clinically Applicable
To cope with all the resulting data, the automation of data
analysis in a clinically applicable way will still require some
efforts. For the development of the assay, the use of Skyline
enabled the parallel processing of all the consortium data, but in
a clinical setting, vendor-specific software is more likely to be
implemented. However, with recent advances in machine
learning in the proteomics field, we are optimistic that a
community effort in data analysis can move forward very
quickly.50 This includes automated diagnosis based on the
MRM data. Initiatives such as EuBIC, prominent advocates of
data sharing, provide the perfect basis for seeding such efforts.
Meeting diagnostic assay criteria required by regulatory
agencies, including calibrators/internal standards, sample
preparation, instrumentation, as well as data review and
reporting, all mentioned and detailed here, requires consid-
eration from a broader deployment perspective. Fortunately,
however, these requirements are understood, as previous efforts
such as the National Cancer Institute’s Clinical Proteomic
Technologies for Cancer initiative and the HUPO Proteomics
Standards Initiative have aided the acceptance and validation
processes by introducing the “verification” concept using MRM
technologies, similarly to the Accreditation Standards concept
and results introduced in this article. Together, this illustrates
that collaboration will be key to the final success of a “fit-for-
purpose” MRM assay.51
In conclusion, we describe the full pipeline for developing an
MS-based assay for viral presence directly on clinical samples
and with conventional instrumentation. The current assay
allows the diagnosis of up to 200 COVID-19 patients per
instrument per day with high viral load. However, our results are
the stepping stone to a second generation assay wherein by
removing matrix with peptide immunopurification, 1 min per
patient would result in up to nearly 1500 patients of potentially
up to Ct 30 on a single LC-MS setup. Sample preparation for
protein detection can be done under $5 worth of reagents.
Therefore, if 1000 patients per instrument can be reached, the
cost of the instrument would soon be covered. Importantly,
however, most clinical laboratories already use tandem quadru-
pole instruments in neonatal diagnostics. As opposed to PCR,
MS can thus be deployed for many other clinical applications
once the pandemic cools down. For sake of pandemic readiness,
we need orthogonal diagnostics to PCR and LCMS is proving a
very promising addition to that toolbox. To make it into the
clinic, however, free sharing of all acquired data will be essential
to intercept matrix and instrumental heterogeneity. At the same
time, we cannot know for sure when this protein-based MS-
based test will be ready for the clinic or when the clinic will be
ready for a protein-based mass spectrometry test. Nevertheless,
it is clear that mass spectrometry stands a chance of matching
PCR’s output and economies of scale, if a collective effort by the
community is applied. The UK is currently setting the scene,
building on collaborative efforts like COVID-MSC25 and Cov-
MS and others will most likely follow. What is certain is that not
trying would be scientifically negligent given the critical
importance of the issue.
■ MATERIALS AND METHODS
Sample Preparation
In the discovery phase (blue), 50 μL of a UTM-RT patient sample was
precipitated by adding 450 μL (9 volumes) of ice-cold acetone (−20
°C). After spinning at 16000g and 0 °C, the supernatant was discarded
and 1 μg of trypsin/Lys-C mix (Promega) in 60 μL 500 mM
triethylammonium bicarbonate (TEABC) buffer was added. This was
followed by an incubation step of 4 h at 37 °C to facilitate trypsin
digestion. Next, 20 μL of this sample was prepared for analysis in a final
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concentration of 0.1% formic acid of which 2 μL was injected into the
LC-MS system. In the consortium phase (red), the protocol was
validated on a dilution series of two recombinant COVID-19 proteins
NCAP_SARS2 and SPIKE_SARS2 (Sino Biological, Beijing, China)
which were found to be most abundant in public data on SARS-CoV-
2.17,23 A triplicate dilution series of 250 μL of negative patient Copan
UTM-RT medium was spiked with different amounts of recombinant
protein (500, 100, 50,10, 5, 1, 0.5, 0.1, 0.05, 0 ng) resulting in a
concentration range of 1 ng to 300 fg on column. Within the Cov-MS
consortium, multiple sample preparation protocols were tested (see
Detailed Methods section), which led to the following protocol for the
clinical phase (green). A direct ice-cold acetone precipitation (7
volumes) on 175 μL of medium in 1.5 mL Eppendorf Protein LoBind
tubes, resuspending this in 35 μL 50 mM TEABC 0.5 μg trypsin/LysC
and 5% acetonitrile with 10 ng of Cov-MS QConCAT standard,
digesting for 15 min at 37 °C, followed by addition of 3.5 μL of 10%
formic acid (end concentration 1%) andpossibly following SPE
injecting 10 μL on column. The preliminary peptide immunopur-
ification (SISCAPA) data (Supplementary Data 22) were obtained by
performing the protocol described by Razavi et al.46 using polyclonal
antibodies targeting two NCAP peptides: AYNVTQAFGR and
DGIIWVATEGALNTPK.
Data Acquisition
For each peptide, the cone and collision energies were optimized within
8 min runs as described in the SOP (Supplementary Data 12). A
scheduled MRM file was created, retaining the most sensitive peptides
on each instrumental platform based on human inspection.
Instrumental parameters are given in more detail in the Supporting
Information, Detailed Methods section. Vendor-specific application
notes are available online.35−38
Data Analysis
The data were analyzed in Skyline Daily (version 20.1.9.234) using a
template file containing the 17 target peptides. Peak boundaries were
manually adjusted, as this was required, considering the amount of
interfering transitions, originating from the matrix. Note that adjusting
the peak boundaries could be considered as a subjective task which
might introduce bias in the data analysis.
Data Availability
The mass spectrometry data generated during the current study are
being shared through the Skyline Panorama Public interface for easy
accessibility (https://panoramaweb.org/CovMS.url) and are being
deposited to the ProteomeXchange Consortium via the PRIDE partner
repository with data set identifier: PXD022550. The Supporting
Information will bemade available through theMicrosoft Teams group:
“Cov-MS Digital Incubator”. Please send an email to covms@ugent.be
to obtain access.
Code Availability
MS2PIP, DeepLC, EncyclopeDIA, and the Machine Learning
algorithms are open source, licensed under the Apache-2.0 License,






The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/jacsau.1c00048.
Additional figures to highlight the variants of concern for
the NCAP_SARS2 protein and some preliminary
SISCAPA data using a 1 min LC gradient are included;
the detailed methods section describes the different steps
(sample preparation, data acquisition, data analysis, etc.)
in the Cov-MS consortium in more detail (PDF)
Supplementary data (no skyline files/raw data) is
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S.; Sinz, A. Mass Spectrometric Identification of SARS-CoV-2 Proteins
from Gargle Solution Samples of COVID-19 Patients. J. Proteome Res.
2020, 19 (11), 4389.
(12) Giri, R.; Bhardwaj, T.; Shegane, M.; Gehi, B. R.; Kumar, P.;
Gadhave, K.; et al. When Darkness Becomes a Ray of Light in the Dark
Times: Understanding the COVID-19 via the Comparative Analysis of
the Dark Proteomes of SARS-CoV-2, Human SARS and Bat SARS-Like
Coronaviruses. bioRxiv 2020, DOI: 10.1101/2020.03.13.990598.
(13) Grenga, L.; Gallais, F.; Pible, O.; Gaillard, J.-C.; Gouveia, D.;
Batina, H.; Bazaline, N.; Ruat, S.; Culotta, K.; Miotello, G.; Debroas, S.;
Roncato, M.-A.; Steinmetz, G.; Foissard, C.; Desplan, A.; Alpha-Bazin,
B.; Almunia, C.; Gas, F.; Bellanger, L.; Armengaud, J. Shotgun
proteomics of SARS-CoV-2 infected cells and its application to the
optimization of whole viral particle antigen production for vaccines.
Emerging Microbes Infect. 2020, 9, 1712.
(14) Ortea, I.; Bock, J.-O. Re-analysis of SARS-CoV-2 infected host
cell proteomics time-course data by impact pathway analysis and
network analysis. A potential link with inflammatory response. Aging
2020, 12, 11277.
(15) Gordon, D. E.; Jang, G. M.; Bouhaddou, M.; Xu, J.; Obernier, K.;
White, K. M.; O’Meara, M. J.; Rezelj, V. V.; Guo, J. Z.; Swaney, D. L.;
Tummino, T. A.; Huttenhain, R.; Kaake, R. M.; Richards, A. L.;
Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim,M.;
Haas, P.; Polacco, B. J.; Braberg, H.; Fabius, J. M.; Eckhardt, M.;
Soucheray, M.; Bennett, M. J.; Cakir, M.; McGregor, M. J.; Li, Q.;
Meyer, B.; Roesch, F.; Vallet, T.; Mac Kain, A.; Miorin, L.; Moreno, E.;
Naing, Z. Z. C.; Zhou, Y.; Peng, S.; Shi, Y.; Zhang, Z.; Shen,W.; Kirby, I.
T.; Melnyk, J. E.; Chorba, J. S.; Lou, K.; Dai, S. A.; Barrio-Hernandez, I.;
Memon, D.; Hernandez-Armenta, C.; Lyu, J.; Mathy, C. J. P.; Perica, T.;
Pilla, K. B.; Ganesan, S. J.; Saltzberg, D. J.; Rakesh, R.; Liu, X.;
Rosenthal, S. B.; Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin,
Y.; Huang, X.-P.; Liu, Y.; Wankowicz, S. A.; Bohn, M.; Safari, M.; Ugur,
F. S.; Koh, C.; Savar, N. S.; Tran, Q. D.; Shengjuler, D.; Fletcher, S. J.;
O’Neal, M. C.; Cai, Y.; Chang, J. C. J.; Broadhurst, D. J.; Klippsten, S.;
Sharp, P. P.; Wenzell, N. A.; Kuzuoglu-Ozturk, D.; Wang, H.-Y.;
Trenker, R.; Young, J. M.; Cavero, D. A.; Hiatt, J.; Roth, T. L.; Rathore,
U.; Subramanian, A.; Noack, J.; Hubert, M.; Stroud, R. M.; Frankel, A.
D.; Rosenberg, O. S.; Verba, K. A.; Agard, D. A.; Ott, M.; Emerman,M.;
Jura, N.; von Zastrow, M.; Verdin, E.; Ashworth, A.; Schwartz, O.;
d’Enfert, C.; Mukherjee, S.; Jacobson, M.; Malik, H. S.; Fujimori, D. G.;
Ideker, T.; Craik, C. S.; Floor, S. N.; Fraser, J. S.; Gross, J. D.; Sali, A.;
Roth, B. L.; Ruggero, D.; Taunton, J.; Kortemme, T.; Beltrao, P.;
Vignuzzi, M.; Garcia-Sastre, A.; Shokat, K. M.; Shoichet, B. K.; Krogan,
N. J. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals
Drug Targets and Potential Drug-Repurposing. Nature 2020, 583,
459−468.
(16) Orsburn, B. C.; Jenkins, C.; Miller, S. M.; Neely, B. A.; Bumpus,
N. N. In silico approach toward the identification of unique peptides
from viral protein infection: Application to COVID-19. SSRN J. 2020,
DOI: 10.2139/ssrn.3589835.
(17) Davidson, A. D.; Williamson, M. K.; Lewis, S.; Shoemark, D.;
Carroll, M. W.; Heesom, K. J.; Zambon, M.; Ellis, J.; Lewis, P. A.;
Hiscox, J. A.; Matthews, D. A. Characterisation of the transcriptome
and proteome of SARS-CoV-2 using direct RNA sequencing and
tandem mass spectrometry reveals evidence for a cell passage induced
in-frame deletion in the spike glycoprotein that removes the furin-like
cleavage site. Genome Med. 2020, 12, 68.
(18) Grossegesse, M.; Hartkopf, F.; Nitsche, A.; Schaade, L.;
Doellinger, J.; Muth, T. Perspective on Proteomics for Virus Detection
in Clinical Samples. J. Proteome Res. 2020, 19, 4380.
(19)Neuman, B.W.; Buchmeier, M. J. Supramolecular Architecture of
the Coronavirus Particle. Advances in Virus Research; Academic Press
Inc., 2016; pp 1−27.
(20) Swann, H.; Sharma, A.; Preece, B.; Peterson, A.; Eldridge, C.;
Belnap, D. M.; Vershinin, M.; Saffarian, S. Minimal system for assembly
of SARS-CoV-2 virus like particles. Sci. Rep. 2020, 10, 21877.
(21) Cardozo, K. H. M.; Lebkuchen, A.; Okai, G. G.; Schuch, R. A.;
Viana, L. G.; Olive, A. N.; Lazari, C. d. S.; Fraga, A. M.; Granato, C. F.
H.; Pintao, M. C. T.; Carvalho, V. M. Establishing a mass spectrometry-
based system for rapid detection of SARS-CoV-2 in large clinical sample
cohorts. Nat. Commun. 2020, 11 (1), 6201.
(22) Plante, J. A.; Liu, Y.; Liu, J.; Xia, H.; Johnson, B. A.; Lokugamage,
K. G.; Zhang, X.; Muruato, A. E.; Zou, J.; Fontes-Garfias, C. R.;
Mirchandani, D.; Scharton, D.; Bilello, J. P.; Ku, Z.; An, Z.; Kalveram,
B.; Freiberg, A. N.; Menachery, V. D.; Xie, X.; Plante, K. S.; Weaver, S.
C.; Shi, P.-Y. Spike mutation D614G alters SARS-CoV-2 fitness.Nature
2021, 592 (7852), 116.
(23) Bojkova, D.; Klann, K.; Koch, B.; Widera, M.; Krause, D.; Ciesek,
S.; Cinatl, J.; Munch, C. SARS-CoV-2 infected host cell proteomics
reveal potential therapy targets. Nature 2020, 583, 469.
(24) Pino, L. K.; Searle, B. C.; Bollinger, J. G.; Nunn, B.; MacLean, B.;
MacCoss, M. J. The Skyline ecosystem: Informatics for quantitative
mass spectrometry proteomics. Mass Spectrometry Reviews; John Wiley
and Sons Inc., 2020; Vol. 39, pp 229−244.
(25) Struwe, W.; Emmott, E.; Bailey, M.; Sharon, M.; Sinz, A.;
Corrales, F. J. The COVID-19MS Coalitionaccelerating diagnostics,
prognostics, and treatment. The Lancet; Lancet Publishing Group,
2020; Vol. 395, pp 1761−1762.
(26) Perez-Riverol, Y.; Csordas, A.; Bai, J.; Bernal-Llinares, M.;
Hewapathirana, S.; Kundu, D. J; Inuganti, A.; Griss, J.; Mayer, G.;
Eisenacher, M.; Perez, E.; Uszkoreit, J.; Pfeuffer, J.; Sachsenberg, T.;
Yılmaz, S.; Tiwary, S.; Cox, J.; Audain, E.; Walzer, M.; Jarnuczak, A. F;
Ternent, T.; Brazma, A.; Vizcaino, J. A. The PRIDE database and
related tools and resources in 2019: Improving support for
quantification data. Nucleic Acids Res. 2019, 47, D442.
JACS Au pubs.acs.org/jacsau Article
https://doi.org/10.1021/jacsau.1c00048
JACS Au 2021, 1, 750−765
764
(27) Van Puyvelde, B.; Willems, S.; Gabriels, R.; Daled, S.; De Clerck,
L.; Vande Casteele, S.; Staes, A.; Impens, F.; Deforce, D.; Martens, L.;
Degroeve, S.; Dhaenens, M. Removing the Hidden Data Dependency
of DIA with Predicted Spectral Libraries. Proteomics 2020, 20 (3−4),
No. 1900306.
(28) WHO. Laboratory biosafety guidance related to coronavirus
disease (COVID-19), 2020; https://www.who.int/publications/i/
item/laboratory-biosafety-guidance-related-to-coronavirus-disease-
(covid-19) (accessed March 29, 2021).
(29) Zecha, J.; Lee, C. Y.; Bayer, F. P.; Meng, C.; Grass, V.; Zerweck, J.
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2
Research and Testing. Mol. Cell Proteomics 2020, 19 (9), 1503−22.
(30) Gouveia, D.; Grenga, L.; Gaillard, J.; Gallais, F.; Bellanger, L.;
Pible, O.; et al. Shortlisting SARS-CoV-2 Peptides for Targeted Studies
from Experimental Data-Dependent Acquisition Tandem Mass
Spectrometry Data. Proteomics 2020, 20 (14), 2000107.
(31) PyMOL, https://pymol.org/2/ (accessed March 29, 2021).
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Trypsin Miscleavage: Comparison of Kinetic Constants of Problematic
Peptide Sequences. Anal. Chem. 2015, 87, 7636.
(33) Yao, H.; Song, Y.; Chen, Y.; Wu, N.; Xu, J.; Sun, C.; Zhang, J.;
Weng, T.; Zhang, Z.; Wu, Z.; Cheng, L.; Shi, D.; Lu, X.; Lei, J.; Crispin,
M.; Shi, Y.; Li, L.; Li, S. Molecular Architecture of the SARS-CoV-2
Virus. Cell 2020, 183, 730.
(34) Maarten Dhaenens. Cov-MS Consortium Launch (Teams
Meeting). 2020.
(35) Van Oudenhove, L.; Tanna, N.; Claereboudt, J.; Vissers, H.; Van
Puyvelde, B.; Daled, S. Comprehending COVID-19: Multiple Reaction
Monitoring Transition Selection and Optimization Strategies for LC-




cessed March 29, 2021).
(36) Van Oudenhove, L.; Claereboudt, J.; Moore, R.; Vissers, H.; Van
Puyvelde, B.; Daled, S. Comprehending COVID-19: Maximizing LC-
MSDetection Dynamic Range forMultiple ReactionMonitoring Based
SARS-CoV-2 Analysis; https://www.waters.com/waters/library.
htm?locale=en_US&lid=135075039 (accessed March 29, 2021).
(37) Oehrle, S.; Van Oudenhove, L.; Claereboudt, J.; Vissers, H.; Van
Puyvelde, B.; Daled, S. Comprehending COVID-19: Application of
UniSpray and Electrospray Ionization for the Detection of Proteolytic
Digested SARS-CoV-2 Proteins; https://www.waters.com/waters/
library.htm?locale=en_US&lid=135077658 (accessed March 29,
2021).
(38) Lane, C. S.; Van Puyvelde, B.; Van Uytfanghe, K.; Dhaenens, M.
Targeted assay for quantification of proteins from the SARS-CoV-2




(39) Gouveia, D.; Miotello, G.; Gallais, F.; Gaillard, J.-C.; Debroas, S.;
Bellanger, L.; Lavigne, J.-P.; Sotto, A.; Grenga, L.; Pible, O.;
Armengaud, J. Proteotyping SARS-CoV-2 Virus from Nasopharyngeal
Swabs: A Proof-of-Concept Focused on a 3 min Mass Spectrometry
Window. J. Proteome Res. 2020, 19, 4407.
(40) Beynon, R. J.; Doherty, M. K.; Pratt, J. M.; Gaskell, S. J.
Multiplexed absolute quantification in proteomics using artificial
QCAT proteins of concatenated signature peptides. Nat. Methods
2005, 2 (8), 587−9.
(41) Holman, S. W.; Mclean, L.; Eyers, C. E. RePLiCal: A QconCAT
Protein for Retention Time Standardization in Proteomics Studies.
2016; https://pubs.acs.org/sharingguidelines (accessed March 29,
2021).
(42) Peaks of light and heavy peptides have unequal peak boundaries.
MacCoss Lab Software 2020; https://skyline.ms/announcements/
home/support/thread.view?rowId=48979 (accessed March 29, 2021).
(43) Gurdasani, D.; Bear, L.; Bogaert, D.; Burgess, R. A; Busse, R.;
Cacciola, R.; Charpak, Y.; Colbourn, T.; Drury, J.; Friston, K.; Gallo, V.;
Goldman, L. R; Greenhalgh, T.; Hyde, Z.; Kuppalli, K.; Majumder, M.
S; Martin-Moreno, J. M; McKee, M.; Michie, S.; Mossialos, E.; Nouri,
A.; Pagel, C.; Pimenta, D.; Popescu, S.; Priesemann, V.; Rasmussen, A.
L; Reicher, S.; Ricciardi, W.; Rice, K.; Silver, J.; Smith, T. C; Wenham,
C.; West, R.; Yamey, G.; Yates, C.; Ziauddeen, H. The UK needs a
sustainable strategy for COVID-19. Lancet 2020, 396, 1800.
(44) Nikolaev, E. N.; Indeykina, M. I.; Brzhozovskiy, A. G.; Bugrova,
A. E.; Kononikhin, A. S.; Starodubtseva, N. L.; Petrotchenko, E. V.;
Kovalev, G. I.; Borchers, C. H.; Sukhikh, G. T. Mass-Spectrometric
Detection of SARS-CoV-2 Virus in Scrapings of the Epithelium of the
Nasopharynx of Infected Patients via Nucleocapsid N Protein. J.
Proteome Res. 2020, 19, 4393.
(45) Zhang, L.; Fang, X.; Liu, X.; Ou, H.; Zhang, H.; Wang, J.; Li, Q.;
Cheng, H.; Zhang, W.; Luo, Z. Discovery of sandwich type COVID-19
nucleocapsid protein DNA aptamers. Chem. Commun. 2020, 56, 10235.
(46) Razavi, M.; Leigh Anderson, N.; Pope, M. E.; Yip, R.; Pearson, T.
W. High precision quantification of human plasma proteins using the
automated SISCAPA Immuno-MS workflow.New Biotechnol. 2016, 33,
494.
(47) Libin, P.; Willem, L.; Verstraeten, T.; Torneri, A.; Vanderlocht,
J.; Hens, N. Assessing the feasibility and effectiveness of household-
pooled universal testing to control COVID-19 epidemics. PLoS
Comput. Biol. 2021, 17, e1008688.
(48) La Scola, B.; Le Bideau, M.; Andreani, J.; Hoang, V. T.;
Grimaldier, C.; Colson, P.; Gautret, P.; Raoult, D. Viral RNA load as
determined by cell culture as a management tool for discharge of SARS-
CoV-2 patients from infectious disease wards. Eur. J. Clin. Microbiol.
Infect. Dis. 2020, 39 (6), 1059−61.
(49) Echo MS.SCIEX; https://sciex.com/products/integrated-
solutions/Echo-ms.html
(50) Bouwmeester, R.; Gabriels, R.; Van Den Bossche, T.; Martens,
L.; Degroeve, S. The Age of Data-Driven Proteomics: How Machine
Learning Enables Novel Workflows. Proteomics 2020, 20, 1900351.
(51) Carr, S. A.; Abbatiello, S. E.; Ackermann, B. L.; Borchers, C.;
Domon, B.; Deutsch, E. W.; et al. Targeted peptide measurements in
biology andmedicine: Best practices for mass spectrometry-based assay
development using a fit-for-purpose approach. Mol. Cell Proteomics
2014, 13 (3), 907−17.
JACS Au pubs.acs.org/jacsau Article
https://doi.org/10.1021/jacsau.1c00048
JACS Au 2021, 1, 750−765
765
